Nisa Investment Advisors LLC lifted its stake in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 4,732.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,707 shares of the company’s stock after purchasing an additional 15,382 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Amneal Pharmaceuticals were worth $349,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in shares of Amneal Pharmaceuticals during the second quarter worth approximately $120,000. Neuburgh Advisers LLC acquired a new position in Amneal Pharmaceuticals during the second quarter worth $123,000. Great West Life Assurance Co. Can acquired a new position in Amneal Pharmaceuticals during the second quarter worth $130,000. Sei Investments Co. acquired a new position in Amneal Pharmaceuticals during the second quarter worth $139,000. Finally, Riverhead Capital Management LLC acquired a new position in Amneal Pharmaceuticals during the second quarter worth $141,000. Institutional investors and hedge funds own 32.39% of the company’s stock.
Amneal Pharmaceuticals stock opened at $19.67 on Friday. The company has a current ratio of 2.01, a quick ratio of 1.25 and a debt-to-equity ratio of 2.85. The firm has a market capitalization of $5.51 billion, a price-to-earnings ratio of 29.30, a PEG ratio of 0.87 and a beta of 1.41. Amneal Pharmaceuticals Inc has a fifty-two week low of $13.47 and a fifty-two week high of $24.48.
Amneal Pharmaceuticals (NYSE:AMRX) last posted its earnings results on Thursday, August 9th. The company reported $0.24 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.01. The company had revenue of $462.33 million for the quarter, compared to analyst estimates of $460.82 million. Amneal Pharmaceuticals had a negative return on equity of 8.74% and a negative net margin of 52.94%. The business’s revenue for the quarter was down 2.5% compared to the same quarter last year. Equities analysts predict that Amneal Pharmaceuticals Inc will post 0.94 EPS for the current year.
A number of brokerages recently weighed in on AMRX. Canaccord Genuity upped their price objective on Amneal Pharmaceuticals from $18.00 to $21.00 and gave the stock a “hold” rating in a report on Tuesday, August 14th. SunTrust Banks lowered Amneal Pharmaceuticals from a “buy” rating to a “hold” rating and set a $15.00 price objective on the stock. in a report on Tuesday, October 16th. Zacks Investment Research lowered Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 17th. ValuEngine raised Amneal Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 3rd. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $35.00 price objective on shares of Amneal Pharmaceuticals in a report on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $22.75.
In other Amneal Pharmaceuticals news, SVP Nikita Shah sold 50,000 shares of the company’s stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $23.46, for a total value of $1,173,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Bryan M. Reasons sold 11,698 shares of the company’s stock in a transaction on Tuesday, August 21st. The shares were sold at an average price of $23.65, for a total value of $276,657.70. The disclosure for this sale can be found here. 3.20% of the stock is currently owned by corporate insiders.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Recommended Story: Day Trading
Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals Inc (NYSE:AMRX).
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.